The European Medicines Agency is to review a regulatory submission from Swiss gene editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and partner Vertex Pharmaceutical (Nasdaq: VRTX).
The companies have submitted for approval of the gene therapy candidate exagamglogene autotemcel (exa-cel) formerly known as CTX001, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
The submission is backed by positive data from two global Phase III studies, which tested exa-cel)= as a potential one-time curative treatment for people with SCD or TDT.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze